Cardiovascular Disease

Cardiovascular disease kills 17.9 million people annually. Despite decades of progress with statins, significant residual risk remains. Inflammation—beyond lipids—drives this risk. These eight hypotheses address the immune-heart axis.

Hypotheses

17.9M

Deaths/Year

Cause of Death

Foundation

The CANTOS trial proved inflammation drives cardiovascular events independent of LDL. Ridker's landmark study showed canakinumab reduced events in patients with elevated hsCRP—without lowering cholesterol. This validated decades of research connecting inflammation to atherosclerosis and opens new therapeutic frontiers.

Hypotheses

CV-1

Inflammation as Independent Risk Factor

Prior Work

CANTOS demonstrated that targeting IL-1β with canakinumab reduced cardiovascular events by 15% without affecting lipids. COLCOT showed colchicine reduced events post-MI. The inflammatory hypothesis is proven—now optimization is needed.

Prediction

Anti-inflammatory therapy will reduce cardiovascular events independent of lipid lowering in patients with elevated hsCRP (>2 mg/L) who have achieved LDL goals.

Key Literature

Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131.
Tardif JC, et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med. 2019;381(26):2497-2505.

CV-2

Comprehensive Immune Profiling for Residual Risk

Prediction

Comprehensive immune profiling (beyond hsCRP) will identify patients with high inflammatory residual risk despite optimal LDL control, enabling targeted anti-inflammatory therapy.

CV-3

Gut Microbiome-Cardiovascular Axis

Mechanistic Basis

TMAO (trimethylamine N-oxide), produced by gut microbiota from dietary choline and carnitine, promotes atherosclerosis. Hazen's group demonstrated elevated TMAO predicts cardiovascular events.

Prediction

TMAO-producing gut microbiome signatures will predict cardiovascular events; microbiome modification (diet, probiotics, or targeted intervention) will reduce risk.

Key Literature

Wang Z, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.

CV-4

Post-MI Immune Response Prediction

Prediction

Immune response patterns in the first 72 hours post-MI will predict heart failure development and remodeling outcomes. Early immune modulation may prevent adverse remodeling.

CV-5

Clonal Hematopoiesis and Cardiovascular Risk

Mechanistic Basis

CHIP (clonal hematopoiesis of indeterminate potential) drives inflammation through mutant leukocyte populations. Jaiswal and colleagues demonstrated 2-4× increased cardiovascular risk in CHIP carriers.

Prediction

CHIP status should be incorporated into cardiovascular risk assessment; CHIP carriers will benefit from earlier and more aggressive anti-inflammatory intervention.

Key Literature

Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121.

CV-6

Heart Failure Immune Subtypes

Prediction

HFpEF and HFrEF represent different immune-metabolic states; immunomodulation will benefit specific subtypes while standard HF therapy remains the backbone of treatment.

CV-7

Atrial Fibrillation-Inflammation Link

Prediction

Anti-inflammatory therapy will reduce AF recurrence after cardioversion/ablation in patients with elevated inflammatory markers.

CV-8

Autoimmunity-Cardiovascular Convergence

Prediction

Aggressive early anti-inflammatory treatment in autoimmune disease will reduce long-term cardiovascular mortality beyond standard care. RA, lupus, and psoriasis patients are cardiovascular patients.

← All Research Domains